XBiotech Inc (OQ:XBIT)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: Building 4, 8201 E Riverside Dr Ste 100
AUSTIN TX 78744-1602
Tel: N/A
Website: N/A
Key People
John Simard
Chairman of the Board, President, Chief Executive Officer, Founder
Sushma Shivaswamy
Chief Scientific Officer
Queena Clark Han
Vice President - Finance and Human Resources, Secretary
Business Overview
XBiotech Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system. Xilonix is a therapeutic antibody, which specifically neutralizes interleukin-1 alpha (IL-1a). Its pipeline includes various human antibodies for treating diseases, such as cancer, vascular disease, inflammatory skin disease and diabetes. The Company has completed a Phase III study in Europe for the treatment of symptomatic colorectal cancer. It also investigated its lead product candidate in clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS).
Financial Overview
For the six months ended 30 June 2020, XBiotech Increvenues increased from $0K to $28.2M. Net loss decreased41% to $6.9M. Revenues reflect an increase in demand forthe Company's products and services due to favorable marketconditions. Lower net loss reflects Research andDevelopment decrease of 79% to $1.4M (expense), InterestIncome increase from $129K to $2.2M (income).
Employees: 78 as of Jun 30, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $256.74M as of Jun 30, 2020
Annual revenue (TTM): $28.18M as of Jun 30, 2020
EBITDA (TTM): -$25.84M as of Jun 30, 2020
Net annual income (TTM): $673.49M as of Jun 30, 2020
Free cash flow (TTM): -$81.95M as of Jun 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 28,989,172 as of Aug 10, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.